# 1st Gen Model Vertex Pharmaceuticals Incorporated Pharmaceutical preparations
at 20-oct-2017
VRTX
Model's trade recommendations -0.86% Return for period
1.42% Annual return
$38.99B Market Cap
β 1.73
VRTX
Model (following trade recommendations)VRTX
Underlying stockS&P 500
Index- STRONG BUY Analysts consensus recommendation
Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for Vertex Pharmaceuticals Incorporated (VRTX) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Sept. 30, 2015.
Market data for VRTX model training are being downloaded from the Quandl premium datasets on a daily basis.
Model is being retrained on a daily basis.
| Float | 248M |
| P/E | 572.70 |
| Shares Outstanding | 252M |
| % Held by Insiders | 1.80% |
| % Held by Institutions | 92.93% |
| EPS (last reported FY) | $-0.11 |
| EPS (last reported Q) | $0.10 |
| EPS, estimated (last reported Q) | $0.06 |
| Total revenues | $2 B |
| Net income | $-0 B |